Larimar Therapeutics Inc (LRMR) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Larimar Therapeutics Inc   (NASDAQ: LRMR)


Larimar Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Larimar Therapeutics Inc's ROI in the second quarter of 2026?
Larimar Therapeutics Inc recorded a cumulative net loss of $-173 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -134.02%.

Within the Healthcare sector 123 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3779 to 4017.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -20.74 % -31.68 % -40.4 % -20.4 % 2.33 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 131 161 81 142 123
Return On Investment (TTM) -134.02 % -130.87 % -133.97 % -89.57 % -61.41 %
LRMR's Overall Ranking # 4017 # 3779 # 3211 # 3531 # 3069
Seq. Investment Change TTM 1.54 % 2.57 % -16.09 % -9.31 % -12.48 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -173 -166 -166 -132 -100




Return On Investment LRMR's Ranking
Within: No.
Industry # 39
Sector # 124
Overall # 4017

Return On Investment Statistics
High Average Low
-28.72 %
-53.85 %
-133.97 %
(Jun 30 2023)   (Dec 31 2025)







Financial Statements
Larimar Therapeutics Inc's II. Quarter Investments $ 131 Millions LRMR's Balance sheet
Larimar Therapeutics Inc's II. Quarter Income $ -33 Millions Quarterly LRMR's Income Statement
LRMR's Income by Division See LRMR's Income by Division


LRMR Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 81 176 86 116 70
Y / Y Investment Growth -53.92 % 103.48 % -25.3 % 65.71 % -27.04 %
Net Income in Millions -166 -81 -37 -35 -51
Y / Y Net Income Growth - - - - -
Annual Return On Investment -204.42 % -45.83 % -42.75 % -30.56 % -72.52 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LRMR's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LRMR's Competitors
Subscribers only: Roi for Larimar Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for LRMR's Customers

Other Ratios
LRMR's Roa LRMR's Inventory Turnover Ratio LRMR's Growth Rates LRMR's Dividend Statistics
LRMR's Profitability Ratios LRMR's Asset Turnover Ratio LRMR's Dividend Growth
LRMR's Roe LRMR's Valuation Ratios LRMR's Financial Strength Ratios LRMR's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-08-31T03:09:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.